Pub. Date : 2019 Dec
PMID : 31669155
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. | lorlatinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | BACKGROUND: Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most known resistance mutations in ALK and ROS1. | lorlatinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 3 | BACKGROUND: Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most known resistance mutations in ALK and ROS1. | lorlatinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 4 | INTERPRETATION: Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC, including those with CNS metastases and those previously treated with crizotinib. | lorlatinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |